Evaluation of 68Ga-N188 PETCT Imaging to Detect Nectin-4 in Cancer Patients

What this Trial Is About

Nectin-4 is a protein involved in cell adhesion that is found in specific normal tissues but is overexpressed in various cancers, especially those originating from epithelial cells such as uroepithelial carcinoma. This makes Nectin-4 a promising target for imaging to help diagnose and study these malignancies. Researchers are evaluating a new PET imaging agent called 68GaN188 that specifically targets Nectin-4 in cancers, including bladder cancer. In this study, participants with suspected or confirmed cancer will receive an intravenous injection of 68GaN188 at a dose of 0.06-0.08 mCikg. After the injection, they will undergo PET imaging using this agent. Additionally, participants will have a whole-body 18F-FDG PETCT scan within one week to compare imaging results. This interventional study is conducted without masking or blinding. Participants will be monitored for up to one year to assess how well the 68GaN188 PETCT scans diagnose malignant tumors. Researchers will also evaluate the radiation dose participants receive from 68GaN188, quantitatively analyze the imaging, and compare the imaging results with pathological findings of the tumors. The study involves informed consent, and safety is monitored throughout the trial period.

68Ga-N188 PET/CT Imaging in Malignancy